Literature DB >> 21536970

Using polymorphisms in FKBP5 to define biologically distinct subtypes of posttraumatic stress disorder: evidence from endocrine and gene expression studies.

Divya Mehta1, Mariya Gonik, Torsten Klengel, Monika Rex-Haffner, Andreas Menke, Jennifer Rubel, Kristina B Mercer, Benno Pütz, Bekh Bradley, Florian Holsboer, Kerry J Ressler, Bertram Müller-Myhsok, Elisabeth B Binder.   

Abstract

CONTEXT: Polymorphisms in the gene encoding the glucocorticoid receptor (GR) regulating co-chaperone FKBP5 have been shown to alter GR sensitivity and are associated with an increased risk to develop posttraumatic stress disorder (PTSD).
OBJECTIVE: To investigate interactions of the FKBP5 single-nucleotide polymorphism rs9296158 and PTSD symptoms on baseline cortisol level, low-dose dexamethasone suppression, and whole-blood gene expression.
DESIGN: Association of FKBP5 genotypes and PTSD symptoms with endocrine measures and genome-wide expression profiles.
SETTING: Waiting rooms of general medical and gynecological clinics of an urban hospital at Emory University. PARTICIPANTS: The 211 participants were primarily African American (90.05%) and of low socioeconomic status and had high rates of trauma and PTSD. MAIN OUTCOME MEASURES: Baseline and post-dexamethasone suppression cortisol measures and gene expression levels.
RESULTS: In our endocrine study, we found that only risk allele A carriers of rs9296158 showed GR supersensitivity with PTSD; in contrast, baseline cortisol levels were decreased in PTSD only in patients with the GG genotype. Expression of 183 transcripts was significantly correlated with PTSD symptoms after multiple testing corrections. When adding FKBP5 genotype and its interaction with PTSD symptoms, expression levels of an additional 32 genes were significantly regulated by the interaction term. Within these 32 genes, previously reported PTSD candidates were identified, including FKBP5 and the IL18 and STAT pathways. Significant overrepresentation of steroid hormone transcription factor binding sites within these 32 transcripts was observed, highlighting the fact that the earlier-described genotype and PTSD-dependent differences in GR sensitivity could drive the observed gene expression pattern. Results were validated by reverse transcriptase-polymerase chain reaction and replicated in an independent sample (N = 98).
CONCLUSIONS: These data suggest that the inheritance of GR sensitivity-moderating FKBP5 polymorphisms can determine specific types of hypothalamic-pituitary-adrenal axis dysfunction within PTSD, which are also reflected in gene-expression changes of a subset of GR-responsive genes. Thus, these findings indicate that functional variants in FKBP5 are associated with biologically distinct subtypes of PTSD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536970      PMCID: PMC3686481          DOI: 10.1001/archgenpsychiatry.2011.50

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  54 in total

1.  Comparison of the PTSD Symptom Scale-Interview Version and the Clinician-Administered PTSD scale.

Authors:  E B Foa; D F Tolin
Journal:  J Trauma Stress       Date:  2000-04

2.  Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data.

Authors:  Christian Ramakers; Jan M Ruijter; Ronald H Lekanne Deprez; Antoon F M Moorman
Journal:  Neurosci Lett       Date:  2003-03-13       Impact factor: 3.046

3.  JASPAR: an open-access database for eukaryotic transcription factor binding profiles.

Authors:  Albin Sandelin; Wynand Alkema; Pär Engström; Wyeth W Wasserman; Boris Lenhard
Journal:  Nucleic Acids Res       Date:  2004-01-01       Impact factor: 16.971

4.  An in vitro bioassay to determine individual sensitivity to glucocorticoids: induction of FKBP51 mRNA in peripheral blood mononuclear cells.

Authors:  Harry Vermeer; Brenda I Hendriks-Stegeman; Denise van Suylekom; Ger T Rijkers; Sylvia C van Buul-Offers; Maarten Jansen
Journal:  Mol Cell Endocrinol       Date:  2004-04-15       Impact factor: 4.102

5.  Network analysis of positional candidate genes of schizophrenia highlights myelin-related pathways.

Authors:  T Rietkerk; M P M Boks; I E C Sommer; S de Jong; R S Kahn; R A Ophoff
Journal:  Mol Psychiatry       Date:  2009-04       Impact factor: 15.992

6.  Neuroendocrine aspects of PTSD.

Authors:  R Yehuda
Journal:  Handb Exp Pharmacol       Date:  2005

7.  Association between the dopamine transporter gene and posttraumatic stress disorder.

Authors:  R H Segman; R Cooper-Kazaz; F Macciardi; T Goltser; Y Halfon; T Dobroborski; A Y Shalev
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

8.  Low urinary cortisol excretion in patients with posttraumatic stress disorder.

Authors:  R Yehuda; S M Southwick; G Nussbaum; V Wahby; E L Giller; J W Mason
Journal:  J Nerv Ment Dis       Date:  1990-06       Impact factor: 2.254

9.  Urinary free-cortisol levels in posttraumatic stress disorder patients.

Authors:  J W Mason; E L Giller; T R Kosten; R B Ostroff; L Podd
Journal:  J Nerv Ment Dis       Date:  1986-03       Impact factor: 2.254

10.  Co-twin control study of relationships among combat exposure, combat-related PTSD, and other mental disorders.

Authors:  Karestan C Koenen; Michael J Lyons; Jack Goldberg; John Simpson; Wesley M Williams; Rosemary Toomey; Seth A Eisen; William True; Ming T Tsuang
Journal:  J Trauma Stress       Date:  2003-10
View more
  79 in total

Review 1.  Molecular and cell signaling targets for PTSD pathophysiology and pharmacotherapy.

Authors:  Richard L Hauger; J Alberto Olivares-Reyes; Frank M Dautzenberg; James B Lohr; Sandra Braun; Robert H Oakley
Journal:  Neuropharmacology       Date:  2011-11-25       Impact factor: 5.250

Review 2.  Understanding risk for psychopathology through imaging gene-environment interactions.

Authors:  Luke W Hyde; Ryan Bogdan; Ahmad R Hariri
Journal:  Trends Cogn Sci       Date:  2011-08-10       Impact factor: 20.229

Review 3.  DNA methylation correlates of PTSD: Recent findings and technical challenges.

Authors:  Filomene G Morrison; Mark W Miller; Mark W Logue; Michele Assef; Erika J Wolf
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2018-11-30       Impact factor: 5.067

Review 4.  Fear extinction and BDNF: translating animal models of PTSD to the clinic.

Authors:  R Andero; K J Ressler
Journal:  Genes Brain Behav       Date:  2012-05-11       Impact factor: 3.449

Review 5.  The Psychiatric Genomics Consortium Posttraumatic Stress Disorder Workgroup: Posttraumatic Stress Disorder Enters the Age of Large-Scale Genomic Collaboration.

Authors:  Mark W Logue; Ananda B Amstadter; Dewleen G Baker; Laramie Duncan; Karestan C Koenen; Israel Liberzon; Mark W Miller; Rajendra A Morey; Caroline M Nievergelt; Kerry J Ressler; Alicia K Smith; Jordan W Smoller; Murray B Stein; Jennifer A Sumner; Monica Uddin
Journal:  Neuropsychopharmacology       Date:  2015-04-23       Impact factor: 7.853

Review 6.  Recent Genetics and Epigenetics Approaches to PTSD.

Authors:  Nikolaos P Daskalakis; Chuda M Rijal; Christopher King; Laura M Huckins; Kerry J Ressler
Journal:  Curr Psychiatry Rep       Date:  2018-04-05       Impact factor: 5.285

7.  Dexamethasone Treatment Leads to Enhanced Fear Extinction and Dynamic Fkbp5 Regulation in Amygdala.

Authors:  Takehito Sawamura; Torsten Klengel; Antonio Armario; Tanja Jovanovic; Seth D Norrholm; Kerry J Ressler; Raül Andero
Journal:  Neuropsychopharmacology       Date:  2015-07-15       Impact factor: 7.853

Review 8.  Neuroimaging genetic approaches to Posttraumatic Stress Disorder.

Authors:  Lauren A M Lebois; Jonathan D Wolff; Kerry J Ressler
Journal:  Exp Neurol       Date:  2016-04-22       Impact factor: 5.330

Review 9.  The molecular bases of the suicidal brain.

Authors:  Gustavo Turecki
Journal:  Nat Rev Neurosci       Date:  2014-10-30       Impact factor: 34.870

10.  Association of FKBP5 polymorphisms and resting-state activity in a frontotemporal-parietal network.

Authors:  R A Bryant; K L Felmingham; B Liddell; P Das; G S Malhi
Journal:  Transl Psychiatry       Date:  2016-10-18       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.